Floatz logo

Cytosin-Arabinosid

Adult Acute Lymphocytic Leukemia

PETHEMA FoundationPhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Adult Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
ASPARAGINASE
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →